MSAA Receives Recognition and an Award for MS Conversations Blog and Changing Lives Monday to Sunday Video

The Multiple Sclerosis Association of America (MSAA) is proud to announce two exciting achievements! MSAA’s MS Conversations blog has been included in Medical News Today’s Best Multiple Sclerosis Blogs feature. Additionally, MSAA’s Changing Lives Monday to Sunday video has been selected as a Spring 2017 Digital Health Awards winner in the Bronze category! The 19th […]

Read News Article

The Multiple Sclerosis Association of America Publishes New Resources

The Multiple Sclerosis Association of America is pleased to announce three new resources for the multiple sclerosis (MS) community. These new publications are available free-of-charge as both printed and online versions on mymsaa.org. MSAA’s award-winning magazine, The Motivator, provides valuable information and support for individuals living with MS, their care partners, family members, and medical […]

Read News Article

MS Research Update 2017 Order Form

Shipping Information * Indicates required field * Quantity: Multiple copies are available to medical professionals and groups only Company Name * First Name * Last Name * Street Address Suite/Apt * City * State * Zip * Daytime Phone * Email Address * Anti-Spam    check box please MSAA will ship via US Mail. For […]

Read News Article

Ozanimod (formerly RPC1063)

In this Section Main Article FDA-Approved Medications Experimental Medications New Directions in MS Research Closing Notes Approved Long-Term Treatments for MS (PDF) References Experimental Medications: NEW S1P Receptor Modulators Company: Celegne Oral medication studied at several doses Being studied in RRMS Previous: Siponimod | Next: Ponesimod Ozanimod (RPC1063) is a selective modulator of one type […]

Read News Article

Siponimod (BAF312)

In this Section Main Article FDA-Approved Medications Experimental Medications New Directions in MS Research Closing Notes Approved Long-Term Treatments for MS (PDF) References Experimental Medications: NEW S1P Receptor Modulators Company: Novartis Oral medication studied at several doses Being studied in SPMS Previous: Ofatumumab | Next: Ozanimod Siponimod is a drug with a mechanism of action […]

Read News Article

Ofatumumab (also known as Arzerra®)

In this Section Main Article FDA-Approved Medications Experimental Medications New Directions in MS Research Closing Notes Approved Long-Term Treatments for MS (PDF) References Experimental Medications: Monoclonal Antibody Medications Company: Novartis Given via IV infusion and also studied via subcutaneous injection Being studied in RRMS Previous: Rituxan | Next: Siponimod Like Rituxan and Ocrevus, ofatumumab is […]

Read News Article

Rituxan® (rituximab)

In this Section Main Article FDA-Approved Medications Experimental Medications New Directions in MS Research Closing Notes Approved Long-Term Treatments for MS (PDF) References Experimental Medications: Monoclonal Antibody Medications Company: Genentech and Biogen Administered via IV infusion Being studied in both RRMS and SPMS Previous: Laquinimod | Next: Ofatumumab Rituxan is a monoclonal antibody (CD20, from […]

Read News Article

Laquinimod (also known as Nerventra®)

In this Section Main Article FDA-Approved Medications Experimental Medications New Directions in MS Research Closing Notes Approved Long-Term Treatments for MS (PDF) References Experimental Medications: Administered Orally Company: Teva Neuroscience, Inc. and Active Biotech Oral medication taken once daily; dosing TBD Being studied in RRMS and PPMS Previous: Gilenya | Next: Rituxan Although its exact […]

Read News Article

Gilenya® (fingolimod)

In this Section Main Article FDA-Approved Medications Experimental Medications New Directions in MS Research Closing Notes Approved Long-Term Treatments for MS (PDF) References FDA-Approved Medications: New Data Company: Novartis 0.5 mg capsule given orally once per day Approved in 2010 for RMS Previous: Tysabri | Next: Laquinimod Gilenya is the first in a class of […]

Read News Article